Esbriet regulatory update

InterMune said it reached an agreement with Germany's Statutory Health Insurance Funds Association (GKV-Spitzenverband) to price idiopathic pulmonary fibrosis (IPF) drug Esbriet pirfenidone at €26,999 ($32,806) per year, which is a 10% discount to the price at which InterMune launched the drug last September. The new price takes effect Sept. 15 and is valid for 2 years, or until the costs of Esbriet to the German healthcare system exceed €50 million ($60.8 million) in any 12-month period, at which point the price will be reevaluated. The product is approved in the EU to treat mild to moderate IPF in adults. ...